Biofrontera AG Sponsored ADR Net Debt/EBITDA

Net Debt/EBITDA of BFAGY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt/EBITDA growth rates and interactive chart.


Highlights and Quick Summary

  • Net Debt/EBITDA for the quarter ending June 30, 2022 was 0.01 (a -100.3% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt/EBITDA decreased by -99.17%
  • Annual Net Debt/EBITDA for 2021 was 0.11 (a 1.6% increase from previous year)
  • Annual Net Debt/EBITDA for 2021 was 0.11 (a -103.77% decrease from previous year)
  • Annual Net Debt/EBITDA for 2020 was -2.98 (a -88.72% decrease from previous year)
Visit stockrow.com/BFAGY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt/EBITDA of Biofrontera AG Sponsored ADR

Most recent Net Debt/EBITDAof BFAGY including historical data for past 10 years.

Interactive Chart of Net Debt/EBITDA of Biofrontera AG Sponsored ADR

Biofrontera AG Sponsored ADR Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.01 -3.5
2021 0.15 1.26 0.0 3.44 0.11
2020 0.0 -3.56 0.0 -2.22 -2.98
2019 0.0 0.0 0.44 -0.55
2018 2.08 0.37
2017 0.28 2.58 -0.07
2016 -3.98 1.15

Business Profile of Biofrontera AG Sponsored ADR

Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic